Sugi Predict

Sugi Predict / Compounds / SCHEMBL23070575

SCHEMBL23070575

SCHEMBL23070575

Cn1cc(B2OC(C)(C)C(C)(C)O2)c(OCc2ccccc2)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DGAT1 O75907 1/20 0.45
▸ CNR1 P21554 2/20 0.39
▸ ACHE P22303 2/20 0.39
▸ CNR2 P34972 2/20 0.39
▸ HTR2A P28223 1/20 0.39
▸ HTR2C P28335 1/20 0.39
▸ SLC6A4 P31645 1/20 0.39
▸ ADORA3 P0DMS8 2/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ ADORA2A P29274 1/20 0.37
▸ ADORA1 P30542 1/20 0.37
▸ PKM P14618 1/20 0.37
▸ DAPK1 P53355 1/20 0.37
▸ BRD4 O60885 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19253537 0.86 UCHL1 (0.46) DGAT1CNR1ACHECNR2HRH4
SCHEMBL1360465 0.77 DGAT1 (0.47) DGAT1CNR1ACHECNR2HTR2A
SCHEMBL38660383 0.77 MEN1 (0.36) DGAT1ADORA3ALDH1A1L3MBTL1HRH4
SCHEMBL31002129 0.77 DGAT1 (0.47) DGAT1ALDH1A1TSHRPKMBRD4
SCHEMBL23858552 0.76 UCHL1 (0.35) —
SCHEMBL2487182 0.76 PIN1 (0.49) DGAT1CNR1ACHECNR2HTR2A
SCHEMBL31416769 0.76 DGAT1 (0.52) DGAT1ALDH1A1LMNAL3MBTL1
SCHEMBL19585801 0.75 DGAT1 (0.46) DGAT1ALDH1A1LMNAHPGDTSHR
SCHEMBL29532520 0.75 DGAT1 (0.46) DGAT1ALDH1A1LMNAHPGDTSHR
SCHEMBL25482311 0.75 DGAT1 (0.46) DGAT1ALDH1A1LMNAHPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260144795-A1 SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS H. LUNDBECK A/S (DK) 2026-05-28 — — US disclosed
EP-4720076-A1 SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS H. Lundbeck A/S (DK) 2026-04-08 — — EP disclosed
US-12590106-B2 Spiromacrocyclic orexin 2 receptor agonists H. LUNDBECK A/S (DK) 2026-03-31 — — US disclosed
US-20250361223-A1 AMIDE COMPOUNDS AND USES THEREOF HUTCHISON MEDIPHARMA LTD (CN) 2025-11-27 — — US disclosed
US-12435062-B2 Amide compounds and uses thereof HUTCHISON MEDIPHARMA LIMITED (CN) 2025-10-07 — — US disclosed
US-20250263422-A1 SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS H. LUNDBECK A/S (DK) 2025-08-21 — — US disclosed
US-20240425521-A1 SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS H. LUNDBECK A/S (DK) 2024-12-26 — — US disclosed
WO-2024246285-A1 SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS H. LUNDBECK A/S (DK) 2024-12-05 — — WO disclosed
CN-117777103-A Amide compound and application thereof 和记黄埔医药（上海）有限公司 2024-03-29 — — CN disclosed
CN-117720520-A Amide compound and application thereof 和记黄埔医药（上海）有限公司 2024-03-19 — — CN disclosed
CN-117720519-A Amide compound and application thereof 和记黄埔医药（上海）有限公司 2024-03-19 — — CN disclosed
CN-115315422-B Amide compound and application thereof 和记黄埔医药（上海）有限公司 2023-11-07 — — CN disclosed
US-20230174513-A1 AMIDE COMPOUNDS AND USES THEREOF HUTCHISON MEDIPHARMA LIMITED (CN) 2023-06-08 — — US disclosed
US-20230174513-A1 AMIDE COMPOUNDS AND USES THEREOF HUTCHISON MEDIPHARMA LIMITED (CN) 2023-06-08 — — US disclosed
US-20230174513-A1 AMIDE COMPOUNDS AND USES THEREOF HUTCHISON MEDIPHARMA LIMITED (CN) 2023-06-08 — — US disclosed
EP-4126844-A1 AMIDE COMPOUNDS AND USES THEREOF Hutchison Medipharma Limited (CN) 2023-02-08 — — EP disclosed
CN-115315422-A Amide compound and application thereof 和记黄埔医药（上海）有限公司 2022-11-08 — — CN disclosed
WO-2021197276-A1 Amide compounds and uses thereof HUTCHISON MEDIPHARMA LIMITED (CN) 2021-10-07 — — WO disclosed
WO-2021042890-A1 HETEROCYCLIC COMPOUND AND APPLICATION THEREOF AS TRK KINASE INHIBITOR 罗欣药业(上海)有限公司 2021-03-11 — — WO disclosed
WO-2021042890-A1 HETEROCYCLIC COMPOUND AND APPLICATION THEREOF AS TRK KINASE INHIBITOR 罗欣药业(上海)有限公司 2021-03-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260144795-A1 SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS HCRTR2, HCRTR1, CRHR1 DGAT1 2047/4885CNR1 9/4885ACHE 4327/4885
US-20230174513-A1 AMIDE COMPOUNDS AND USES THEREOF ASNS, ASS1, NAT1 DGAT1 674/4885CNR1 672/4885ACHE 332/4885
US-12435062-B2 Amide compounds and uses thereof ASNS, ASS1, NAT1 DGAT1 674/4885CNR1 672/4885ACHE 332/4885
US-12590106-B2 Spiromacrocyclic orexin 2 receptor agonists HCRTR2, HCRTR1, OXER1 DGAT1 1742/4885CNR1 55/4885ACHE 3368/4885
US-20250361223-A1 AMIDE COMPOUNDS AND USES THEREOF ASNS, NAT1, AADAC DGAT1 760/4885CNR1 731/4885ACHE 234/4885
US-20250263422-A1 SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS HCRTR2, HCRTR1, CRHR2 DGAT1 2519/4885CNR1 60/4885ACHE 4116/4885
US-20240425521-A1 SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS HCRTR2, HCRTR1, CRHR2 DGAT1 2519/4885CNR1 60/4885ACHE 4116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.